SENATE RESOLUTION 225--SUPPORTING THE GOALS OF INTERNATIONAL MYALGIC ENCEPHALOMYELITIS/CHRONIC FATIGUE SYNDROME AWARENESS DAY; Congressional Record Vol. 165, No. 87
(Senate - May 23, 2019)
Formatting necessary for an accurate reading of this text may be shown by tags (e.g., <DELETED> or <BOLD>) or may be missing from this TXT display. For complete and accurate display of this text, see the PDF.
[Pages S3117-S3118]
From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]
SENATE RESOLUTION 225--SUPPORTING THE GOALS OF INTERNATIONAL MYALGIC
ENCEPHALOMYELITIS/CHRONIC FATIGUE SYNDROME AWARENESS DAY
Mr. MARKEY (for himself, Ms. Collins, Mr. Cramer, Mr. Blumenthal, Mr.
Coons, Mr. Hoeven, Mr. Booker, Mr. Van Hollen, Mrs. Feinstein, Mr.
King, Ms. Stabenow, Ms. Sinema, Mr. Casey, Ms. Harris, and Ms. Warren)
submitted the following resolution; which was considered and agreed to:
S. Res. 225
Whereas the National Academy of Medicine (referred to in
this preamble as ``NAM''), formerly known as the Institute of
Medicine, has found Myalgic Encephalomyelitis/Chronic Fatigue
Syndrome (referred to in this preamble as ``ME/CFS'') to be
``a serious, chronic, complex, and systemic disease that
frequently and dramatically limits the activities of affected
patients'';
Whereas between 836,000 and 2,500,000 individuals of all
ages, races, and sexes in the United States are believed to
be afflicted with ME/CFS, with millions more afflicted by ME/
CFS worldwide, and the vast majority of individuals with ME/
CFS are undiagnosed or misdiagnosed;
Whereas ME/CFS is approximately 4 times more prevalent in
women than in men;
Whereas ME/CFS is a chronic disease with no known cure and
leaves \1/4\ of individuals with ME/CFS housebound or
bedbound for extended periods of time;
Whereas 50 to 75 percent of individuals with ME/CFS cannot
work or attend school;
Whereas medical expenses and lost productivity related to
ME/CFS cost the economy of the United States an estimated
$17,000,000,000 to $24,000,000,000 annually;
Whereas the cause of ME/CFS is unknown, there is no
diagnostic test for ME/CFS, and there is no treatment for ME/
CFS that is approved by the Food and Drug Administration;
Whereas NAM has noted a ``paucity of research'' on ME/CFS
and that ``more research is essential'';
Whereas the Centers for Disease Control and Prevention has
called ME/CFS ``America's Hidden Health Crisis'';
Whereas individuals with ME/CFS struggle to find doctors to
care for them, and ME/CFS is included in less than \1/3\ of
medical school curricula;
Whereas, in recognition of the dearth of research on ME/CFS
and the profound impact that the disease has on individuals
with ME/CFS and their loved ones and caretakers, the National
Institutes of Health (referred to in this preamble as the
``NIH'') is ``committed to unraveling the underlying biologic
cause(s) of ME/CFS as swiftly as possible, and promoting
research that will inform the development of effective
strategies for treatment and prevention of this devastating
condition'';
Whereas, in 2017, 11 Institutes at the NIH and the Office
of the Director of the NIH contributed more than $7,000,000
in grants to assist in establishing Collaborative Research
Centers and a Data Management Coordinating Center to improve
the coordination of ME/CFS research and help accelerate
understanding of ME/CFS; and
[[Page S3118]]
Whereas, in 2019, May 12 is recognized as International ME/
CFS Awareness Day: Now, therefore, be it
Resolved, That the Senate--
(1) supports the goals of International Myalgic
Encephalomyelitis/Chronic Fatigue Syndrome Awareness Day;
(2) recognizes and affirms the commitment of the United
States to--
(A) supporting research and medical education for Myalgic
Encephalomyelitis/Chronic Fatigue Syndrome; and
(B) promoting awareness among health professionals and the
public about Myalgic Encephalomyelitis/Chronic Fatigue
Syndrome; and
(3) recognizes the continued importance of--
(A) health care professionals and medical researchers who
care for individuals with Myalgic Encephalomyelitis/Chronic
Fatigue Syndrome; and
(B) those who work to discover the cause of, and develop
and improve diagnosis of, treatments for, and a cure for,
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.
____________________